INMD

Rating neutralAI MemoPost-earnings T+3

InMode

As of 2026-08-08/Post-earnings T+3/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

low

Horizon

—

Key catalyst

Q2 2026 earnings follow-up remains unresolved • 2026-08-08

Base target: $16 / p=45% prob

Biggest risk

The deterministic prior is negative, with expected returns of -2.4% over 20 days and -5.1% over 120 days. Missing final earnings detail, uncertain demand recovery, margin pressure, and the possibility that strategic proposals fail or are withdrawn keep downside material.

Invalidation

Break below $13 or thesis failure.

What would change my mind?

A confirmed Q2 result near or above the preliminary revenue range, evidence of U.S. demand recovery, continued share repurchases, or progress toward a strategic transaction could support re-rating from the current $15.12 anchor.

Research note

Recommendation

neutral

Confidence

low

As of

2026-08-08

Base target

$16

p=45%

Bull target

$18

p=25%

Bear target

$13

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

U.S.
aesthetic-demand stabilization is needed for a durable rerating
A confirmed Q2 result near or above the preliminary revenue range, evidence of U.S.

BearKey bullets

Consensus surprise data, analyst target changes, estimate revisions, and post-earnings market-reaction attribution are unavailable.
Final Q2 2026 revenue, EPS, margin, cash-flow, and guidance details were not confirmed in the accessible primary evidence.
Low coverage and loose peers reduce confidence in target-based valuation signals.

WatchKey bullets

Q2 2026 earnings follow-up remains unresolved

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $16 (p=45%)

Target spread vs base: +16% / -19%

Scenario probabilities

Bull Target: $18 (p=25%)Base Target: $16 (p=45%)Bear Target: $13 (p=30%)

Commentary

This is a low-conviction monitoring update rather than a confirmed thesis improvement. Recent attention is elevated because of the acquisition proposals and the scheduled Q2 follow-up, but the packet does not provide final earnings metrics, analyst revisions, or a reliable post-print price-reaction explanation. Social, options, short-interest, and employee-sentiment evidence are unavailable; missing reaction data is not treated as positive evidence.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

U.S. aesthetic-demand stabilization is needed for a durable rerating

Scenarios

Bull Target (Scenario probability)

$18 / p=25% prob

Base Target (Scenario probability)

$16 / p=45% prob

Bear Target (Scenario probability)

$13 / p=30% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.05

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-08
Q2 2026 earnings follow-up remains unresolved
The company’s preliminary release expected Q2 revenue of $95.2M-$95.4M and reiterated FY2026 revenue guidance of $365M-$375M, but the accessible evidence does not confirm final Q2 results, EPS versus consensus, analyst revisions, or the post-release market reaction. The absence of an investor call further limits forward visibility. [#PR-EARNINGS-2026-07-13]
Prob 50.00% • Move 6.00% • Priced-in 75.00%
EVENT2026-09-15
Strategic-proposal process could support an event premium
InMode confirmed receipt of an unsolicited acquisition proposal from Steel Partners and said its independent-director Special Committee would review it; the SEC filing also disclosed that a separate unsolicited proposal from M.N. Business Strategy was extended through September 15, 2026. No transaction is assured. [#SEC-6K-2026-07-10]
Prob 35.00% • Move 12.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

U.S. aesthetic-demand stabilization is needed for a durable rerating
2026-12-31
The prior thesis identified weaker U.S. aesthetic-procedure demand and financing conditions as the core operating constraint, while international growth provided partial offset. A sustained recovery remains unconfirmed because final Q2 operating detail and management commentary are not available in the evidence packet. [#20F-2026-02-10]
Prob 35% • Move 15% • Priced-in 70%

Risks

Consensus surprise data, analyst target changes, estimate revisions, and post-earnings market-reaction attribution are unavailable.
Final Q2 2026 revenue, EPS, margin, cash-flow, and guidance details were not confirmed in the accessible primary evidence.
Low coverage and loose peers reduce confidence in target-based valuation signals.
Strategic proposals may be withdrawn, rejected, modified, or never consummated; no deal certainty should be priced in.
U.S. aesthetic-procedure demand and financing conditions may remain weak, limiting platform sales and profitability.

Peers

Symbol	Summary
BSX	Broad large-cap medical-device benchmark; useful for sector context but not a close aesthetic-device operating comp.
EW	Large-cap medtech benchmark with limited direct product-market overlap; valuation comparison should be heavily discounted for scale and mix differences.
AHCO	Same-sector, similar-market-cap candidate, but the packet does not establish direct overlap with InMode’s aesthetic-device business.
AVR	Small-cap same-sector candidate; loose peer with insufficient evidence of direct operating comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

BSX

Broad large-cap medical-device benchmark; useful for sector context but not a close aesthetic-device operating comp.

Large-cap medtech benchmark with limited direct product-market overlap; valuation comparison should be heavily discounted for scale and mix differences.

AHCO

Same-sector, similar-market-cap candidate, but the packet does not establish direct overlap with InMode’s aesthetic-device business.

AVR

Small-cap same-sector candidate; loose peer with insufficient evidence of direct operating comparability.